|
1. Biologie
|
|
|
|
Mutating DNA caught on film [Science]
|
|
|
|
|
|
According
to its developers, the technique can be applied to assess mutation
dynamics in other types of cells, even human cancer cells. And the
researchers eventually hope to be able to monitor mutation rates real
time in entire organisms, such as zebra fish, to see whether different
tissues have different mutation rates.
|
|
|
|
|
|
|
2.5 Etiologie - Gènes
|
|
|
Matter: What’s Behind Many Mystery Ailments? Genetic Mutations, Study Finds [NY Times]
|
|
|
|
|
|
The
study, published Thursday in Science, represents the first large-scale
search of electronic health records for hidden Mendelian diseases. But
Dr. Joshua C. Denny, a biomedical informatics researcher at the
Vanderbilt University School of Medicine and co-author of the new study,
suspected that it only revealed the tip of a genetic iceberg.
|
|
|
|
|
|
|
3.1 Prévention - Tabac
|
|
|
|
|
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
Adaptimmune shares boosted by new signs of success with TCR cell therapy [EndPoints]
|
|
|
|
|
|
Researchers
tracked two confirmed and one unconfirmed partial tumor responses in
the first group, with the fourth patient stable. By itself, that may not
look like much, but it was actual human data to indicate that their
platform approach to solid tumors — a tough hurdle in cell therapies —
has real potential across multiple tumors.
|
|
|
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
|
5.2 Pharma
|
|
|
MorphoSys eyes MOR208 approval after midphase DLBCL data impress [FierceBiotech]
|
|
|
|
|
|
MorphoSys
will need durability data to make a truly compelling case as the
longer-running CAR-T trials suggest patients on those drugs who are in
remission after six months stay in remission. But with MorphoSys’ data
pointing in the right direction, the German biotech is talking to the
FDA about the possibility of filing for approval based on the midphase
data.
|
|
|
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.9 AACR
|
|
|
AACR Previews Research from Annual Meeting 2018 [Cancer Research Catalyst]
|
|
|
|
|
|
This
year’s Annual Meeting features the theme “Driving Innovative Science to
Patient Care.” In a recent interview, Caligiuri, along with Program
Chair Elaine Mardis, PhD, discussed how the diverse range of program
offerings should appeal to attendees from all parts of the cancer
research continuum.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
|